Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Anticipated CAGR of the Chikungunya Market, and What Factors Will Drive It?
The market for chikungunya has seen considerable growth in the past few years. It is expected that it will increase from $0.59 billion in 2024 to $0.65 billion in 2025, recording a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth in the historic period include a rise in per capita health care spending, an increasing occurrence of newly emerging and re-emerging infectious diseases, growth in personal disposable income, climate change, and enhanced awareness about mosquito-borne diseases.
An impressive expansion is projected for the chikungunya market in the coming years, with a forecasted size of $0.92 billion in 2029 and a compound annual growth rate (CAGR) of 9.2%. This anticipated growth for the forecast period mainly stems from a global surge in clinical trials, an increase in the elderly population, an escalating demand for vaccination, the rise of governmental and non-governmental initiatives, higher governmental investment, and encouraging regulations. Key trends that are expected to influence the forecast period include biotechnological advancements in vaccine creation, emerging opportunities for new vaccines, utilization of CRISPR and AI for inventive solutions, strategic partnerships developed within pharmaceutical companies, and the incorporation of telemedicine services.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21137&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Chikungunya Market?
The forecasted rise in mosquito-borne diseases is anticipated to boost the chikungunya market’s expansion. Global public health faces significant hurdles due to diseases like chikungunya, dengue, and the zika virus, which are transmitted to humans through bites from infected aedes mosquitoes. Factors contributing to a worldwide surge in mosquito-borne disease cases include climate change, urbanization, deforestation, the accumulation of stagnant water, inadequate pest control measures, a rise in global travel, and resistance to insecticides. Chikungunya treatment aids those suffering from such diseases by relieving symptoms like fever, joint pain, and inflammation, boosting overall comfort and mobility, lowering complication risks, and expediting recovery with hydration, pain management, and supportive care. In a case study, the UK Health Security Agency, a UK-government agency, reported that from January to June 2024, the number of dengue cases in returning travellers in England, Wales, and Northern Ireland spiked at 473, a 201% increase from the 157 cases noted during the same time frame in 2023. Thus, the mounting worldwide prevalence of mosquito-borne diseases is stimulating the chikungunya market’s growth.
Which Key Market Segments Comprise the Chikungunya Market and Drive Its Revenue Growth?
The chikungunyamarket covered in this report is segmented –
1) By Type: Antiviral Drugs; Herbal And Complementary Treatments; Supportive Care; Vaccines
2) By Product Form: Liquid Form; Powder; Solid Form
3) By Disease Stage: Acute; Chronic; Post-Infection
4) By Sales Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Supermarkets
5) By End User: Caregivers; Healthcare Professionals; Patients
Subsegments:
1) By Antiviral Drugs: Nucleoside Analogues; Protease Inhibitors
2) By Herbal And Complementary Treatments: Ayurvedic Remedies; Homeopathic Treatments; Traditional Chinese Medicine
3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen); Fluid Therapy; Physiotherapy
4) By Vaccines: Live-Attenuated Vaccines; Inactivated Vaccines; mRNA-Based Vaccines
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21137&type=smp
Which Areas Are Leading Regions in the Chikungunya Market Expansion Across the Globe?
North America was the largest region in the chikungunya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theChikungunya Market Direction?
The focus of significant corporations in the chikungunya market is on creating ground-breaking vaccines that promote immunity, prevent disease spreads, and tackle the escalating global health issue of chikungunya virus infections. A live attenuated chikungunya vaccine, which uses a weakened version of the chikungunya virus to trigger an immune response without causing the disease, ensures enduring protection. Valneva SE, a French biotech company, announced the FDA-approved IXCHIQ, a live attenuated chikungunya vaccine, in November 2023. This endorsement was achieved through accelerated approval based on anti-CHIKV neutralizing antibody titers, with sustained approval contingent on the verification of clinical advantage in further studies. The FDA granted Valneva a Priority Review Voucher (PRV), which the company plans to monetize to fund its research and development initiatives. IXCHIQ is administered as a single-dose muscle injection and includes a live, weakened chikungunya virus strain, which may generate symptoms in recipients similar to those of the chikungunya disease.
View the full report here:
https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report
How Is the Chikungunya Market Conceptually Defined?
Chikungunya (CHIKV) is a viral infection caused by the chikungunya virus, primarily transmitted to humans through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. The virus causes fever, joint pain, headache, rash, and muscle pain, significantly impacting the quality of life of affected individuals.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21137
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model